Showing 2831-2840 of 5646 results for "".
- Lynx Inventory System Now Customized for Retina Specialistshttps://modernod.com/news/lynx-inventory-system-now-customized-for-retina-specialists/2479638/McKesson announced that Lynx, its customizable, cloud-based medication inventory management system for specialty medical practices, has new features designed especially for delivering injectable medication therapies in retina practices. These customizations for retina specialists ensure that each
- FDA Revamping Clearance Procedures for Medical Deviceshttps://modernod.com/news/fda-revamping-clearance-procedures-for-medical-devices/2479649/The FDA is significantly revamping the way it clears most medical devices for U.S. marketing, planning to rely far less on comparisons with much older products already on the market, according to a
- Warby Parker Eyewear Now Available to People Enrolled in UnitedHealthcare Medicare Advantage Planshttps://modernod.com/news/warby-parker-eyewear-now-available-to-people-enrolled-in-unitedhealthcare-medicare-advantage-plans/2479652/For the first time, Warby Parker is accepting Medicare insurance. The company’s designer prescription eyewear is available to approximately 2 million people enrolled in UnitedHealthcare Medicare Advantage plans, either online or at more than 80 Warby Parker stores nationwide, according to a
- 4D Molecular Therapeutics Announces FDA Orphan Drug Designation Granted to 4D-110 for the Treatment of Choroideremiahttps://modernod.com/news/4d-molecular-therapeutics-announces-fda-orphan-drug-designation-granted-to-4d-110-for-the-treatment-of-choroideremia/2479659/Gene therapy company 4D Molecular Therapeutics (4DMT) announced that the FDA has granted orphan drug designation to 4D-110 for the treatment of choroideremia. Choroideremia (CHM) is an X-linked monogenic recessive disease (caused by mutation of the REP-1 gene) starting with reduced night v
- Santen Expands Research and Development Leadership Teamhttps://modernod.com/news/santen-expands-research-and-development-leadership-team/2479666/Santen announced the expansion of its research and development leadership team through the addition of two new executive hires. Reza M. Haque, MD, PhD, has been appointed as Senior Vice President, Global Research and Development Strategy, and Peter Sallstig, MD, MBA
- Prevent Blindness Opens Nominations for 2019 Jenny Pomeroy Award for Excellence in Vision and Public Healthhttps://modernod.com/news/prevent-blindness-opens-nominations-for-2019-jenny-pomeroy-award-for-excellence-in-vision-and-public-health/2479669/Prevent Blindness is issuing a call for nominations for the 2019 Jenny Pomeroy Award for Excellence in Vision and Public Health. The award recognizes an individual, team, or organization that has made an outstanding contribution to the field of public health, and vision and eye health at a commun
- Takeda, Shire Shareholders to Vote on Merger Deal Next Monthhttps://modernod.com/news/takeda-shire-shareholders-to-vote-on-merger-deal-next-month/2479678/Takeda and Shire announced that shareholders will vote on December 5 on the companies’ proposed $62-billion merger, with the Japanese drugmaker targeting January 8, 2019 for closing of the deal. Takeda CEO Christophe Weber remarked “with the date of our extraordinary general meeting (
- EyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for Dexycu by CMShttps://modernod.com/news/eyepoint-pharmaceuticals-announces-assignment-of-permanent-j-code-for-dexycu-by-the-center-for-medicare-and-medicaid-services-cms/2479679/EyePoint Pharmaceuticals announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a specific and permanent reimbursement J-code through the Healthcare Common Procedure Coding System (HCPCS) for Dexycu (dexamethasone intraocular suspension) 9%. Dexycu is the first and only
- Prospective Study for NaturalVue Multifocal Demonstrates Decreased Refractive Error Change in Fast-Progressing Myopic Childrenhttps://modernod.com/news/prospective-study-for-naturalvue-multifocal-demonstrates-decreased-refractive-error-change-in-fast-progressing-myopic-children/2479681/Thomas Aller, OD, presented updated findings from a prospective clinical trial of NaturalVue (etafilcon A) 1 Day Multifocal Contact Lenses at a briefing for media and industry leaders at the American Academy of Optometry (AAO) Conference in San Antonio on November 9. The NaturalVue portfolio of p
- Study Demonstrates Galimedix Therapeutics’ MRZ-99030 Eye Drops Neutralize the Reproduction of Misfolded Amyloid-Betahttps://modernod.com/news/new-in-vitro-study-demonstrates-galimedix-therapeutics-investigational-compound-mrz-99030-eye-drops-neutralizes-the-reproduction-of-misfolded-amyloid-beta/2479684/Galimedix Therapeutics announced the results of a new study at the Society for Neuroscience conference demonstrating that a single application of the investigational compound MRZ-99030, also known as GAL-101, causes sustained prevention of misfolded amyloid beta molecules from aggregating into to